Author

Stephane NANCEY

ACUTE INFUSION REACTIONS UNDER VEDOLIZUMAB IN INFLAMMATORY BOWEL DISEASE PATIENTS: RESULTS OF A MULTICENTER RETROSPECTIVE OBSERVATIONAL COHORT STUDY
ACUTE INFUSION REACTIONS UNDER VEDOLIZUMAB IN INFLAMMATORY BOWEL DISEASE PATIENTS: RESULTS OF A MULTICENTER RETROSPECTIVE OBSERVATIONAL COHORT STUDY

Stephane NANCEY  et al.

HIGH SERUM SUBCUTANEOUS INFLIXIMAB LEVELS ARE ASSOCIATED WITH DEEP REMISSION IN PATIENTS WITH IBD
HIGH SERUM SUBCUTANEOUS INFLIXIMAB LEVELS ARE ASSOCIATED WITH DEEP REMISSION IN PATIENTS WITH IBD

Stephane NANCEY  et al.

IMPACT OF BIOLOGICS ON THE RISK OF EARLY POSTOPERATIVE COMPLICATIONS IN CROHN'S DISEASE: A FRENCH NATIONWIDE STUDY
IMPACT OF BIOLOGICS ON THE RISK OF EARLY POSTOPERATIVE COMPLICATIONS IN CROHN'S DISEASE: A FRENCH NATIONWIDE STUDY

Stephane NANCEY  et al.

USTEKINUMAB IS MORE EFFECTIVE THAN AZATHIOPRINE TO PREVENT ENDOSCOPIC POSTOPERATIVE RECURRENCE IN CROHN´S DISEASE
USTEKINUMAB IS MORE EFFECTIVE THAN AZATHIOPRINE TO PREVENT ENDOSCOPIC POSTOPERATIVE RECURRENCE IN CROHN´S DISEASE

Stephane NANCEY  et al.

PATTERNS OF CORTICOSTEROID EXPOSURE AND EXCESS IN INFLAMMATORY BOWEL DISEASE: RESULTS FROM THE DETERMINANTS, INCIDENCE AND CONSEQUENCES OF CORTICOSTEROID EXCESS (DICE) ONLINE MONITORING TOOL
PATTERNS OF CORTICOSTEROID EXPOSURE AND EXCESS IN INFLAMMATORY BOWEL DISEASE: RESULTS FROM THE DETERMINANTS, INCIDENCE AND CONSEQUENCES OF CORTICOSTEROID EXCESS (DICE) ONLINE MONITORING TOOL

Stephane NANCEY  et al.

PROTON PUMP INHIBITORS ARE ASSOCIATED WITH A DISABLING COURSE OF CROHN’S DISEASE
PROTON PUMP INHIBITORS ARE ASSOCIATED WITH A DISABLING COURSE OF CROHN’S DISEASE

Stephane NANCEY  et al.

COMPARATIVE EFFECTIVENESS OF USTEKINUMAB AND ADALIMUMAB IN THE PREVENTION OF POST-OPERATIVE RECURRENCE IN CROHN’S DISEASE
COMPARATIVE EFFECTIVENESS OF USTEKINUMAB AND ADALIMUMAB IN THE PREVENTION OF POST-OPERATIVE RECURRENCE IN CROHN’S DISEASE

Stephane NANCEY  et al.

SERUM CALPROTECTIN IS NOT EFFECTIVE TO PREDICT IBD RELAPSE AND HAS WEAK DIAGNOSIS ACCURACY
SERUM CALPROTECTIN IS NOT EFFECTIVE TO PREDICT IBD RELAPSE AND HAS WEAK DIAGNOSIS ACCURACY

Stephane NANCEY  et al.

CHANGING THE COURSE OF CROHN’S DISEASE WITH AN EARLY USE OF ADALIMUMAB: THE CURE STUDY FROM THE GETAID
CHANGING THE COURSE OF CROHN’S DISEASE WITH AN EARLY USE OF ADALIMUMAB: THE CURE STUDY FROM THE GETAID

Stephane NANCEY  et al.

IN FAILURE OF NON-OPTIMIZED ADALIMUMAB (ADA) WITH THERAPEUTIC SERUM LEVELS, A CHANGE IN BIOTHERAPY CLASS IS GREATER THAN AN INTENSIFICATION OF ADA DOSE IN PATIENTS WITH CROHN´S DISEASE AND HEMORRHAGIC RECTOCOLITIS
IN FAILURE OF NON-OPTIMIZED ADALIMUMAB (ADA) WITH THERAPEUTIC SERUM LEVELS, A CHANGE IN BIOTHERAPY CLASS IS GREATER THAN AN INTENSIFICATION OF ADA DOSE IN PATIENTS WITH CROHN´S DISEASE AND HEMORRHAGIC RECTOCOLITIS

Stephane NANCEY  et al.

CANCER INCIDENCE IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE AND A PRIOR NON-DIGESTIVE MALIGNANCY ACCORDING TO THE IMMUNOMODULATORY THERAPY: A MULTICENTER COHORT STUDY
CANCER INCIDENCE IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE AND A PRIOR NON-DIGESTIVE MALIGNANCY ACCORDING TO THE IMMUNOMODULATORY THERAPY: A MULTICENTER COHORT STUDY

Stephane NANCEY  et al.

TOFACITINIB OR USTEKINUMAB FOR THIRD-LINE TREATMENT OF REFRACTORY ULCERATIVE COLITIS: A MULTICENTER RETROSPECTIVE PROPENSITY SCORE-MATCHED ANALYSIS
TOFACITINIB OR USTEKINUMAB FOR THIRD-LINE TREATMENT OF REFRACTORY ULCERATIVE COLITIS: A MULTICENTER RETROSPECTIVE PROPENSITY SCORE-MATCHED ANALYSIS

Stephane NANCEY  et al.

IGA VASCULITIS ASSOCIATED WITH INFLAMMATORY BOWEL DISEASES: A MULTICENTER STUDY OF THE GETAID AND GFEV
IGA VASCULITIS ASSOCIATED WITH INFLAMMATORY BOWEL DISEASES: A MULTICENTER STUDY OF THE GETAID AND GFEV

Stephane NANCEY  et al.

EARLY DETECTION OF ANTI-DRUG-ANTIBODIES USING DRUG-TOLERANT ASSAY WITHIN THE INDUCTION PHASE AT WEEK 2 PREDICTS THE LOSS OF CLINICAL RESPONSE TO ANTI-TNF IN INFLAMMATORY BOWEL DISEASE PATIENTS
EARLY DETECTION OF ANTI-DRUG-ANTIBODIES USING DRUG-TOLERANT ASSAY WITHIN THE INDUCTION PHASE AT WEEK 2 PREDICTS THE LOSS OF CLINICAL RESPONSE TO ANTI-TNF IN INFLAMMATORY BOWEL DISEASE PATIENTS

Stephane NANCEY  et al.

DIAGNOSTIC AND PROGNOSTIC VALUES OF ANTI-GLYCOPROTEIN 2 ANTIBODIES (GP2A) IN INFLAMMATORY BOWEL DISEASES: RESULTS OF A RETROSPECTIVE MONOCENTRIC COHORT STUDY
DIAGNOSTIC AND PROGNOSTIC VALUES OF ANTI-GLYCOPROTEIN 2 ANTIBODIES (GP2A) IN INFLAMMATORY BOWEL DISEASES: RESULTS OF A RETROSPECTIVE MONOCENTRIC COHORT STUDY

Stephane NANCEY  et al.

POST-OPERATIVE COURSE OF CROHN´S DISEASE AFTER ILEOCAECAL RESECTION: RESULTS OF A RETROSPECTIVE MONOCENTRIC COHORT STUDY
POST-OPERATIVE COURSE OF CROHN´S DISEASE AFTER ILEOCAECAL RESECTION: RESULTS OF A RETROSPECTIVE MONOCENTRIC COHORT STUDY

Stephane NANCEY  et al.

IMPACT OF ABDOMINOPELVIC RADIOTHERAPY ON INFLAMMATORY BOWEL DISEASE ACTIVITY: A MULTICENTER COHORT STUDY FROM THE GETAID
IMPACT OF ABDOMINOPELVIC RADIOTHERAPY ON INFLAMMATORY BOWEL DISEASE ACTIVITY: A MULTICENTER COHORT STUDY FROM THE GETAID

Stephane NANCEY  et al.

EFFECTIVENESS AND SAFETY OF RISANKIZUMAB INDUCTION THERAPY IN PATIENTS WITH CROHN’S DISEASE: A GETAID COHORT STUDY
EFFECTIVENESS AND SAFETY OF RISANKIZUMAB INDUCTION THERAPY IN PATIENTS WITH CROHN’S DISEASE: A GETAID COHORT STUDY

Stephane NANCEY  et al.

REAL-LIFE EFFECTIVENESS OF TOFACITINIB IN TWO INDICATIONS IN ULCERATIVE COLITIS: A RETROSPECTIVE WORLDWIDE, MULTICENTER, COLLABORATIVE STUDY
REAL-LIFE EFFECTIVENESS OF TOFACITINIB IN TWO INDICATIONS IN ULCERATIVE COLITIS: A RETROSPECTIVE WORLDWIDE, MULTICENTER, COLLABORATIVE STUDY

Stephane NANCEY  et al.

THE OUTCOMES OF PATIENTS TREATED WITH 2ND AND 3RD LINE BIOLOGICAL IN PERIANAL CROHN’S DISEASE (PCD) – A MULTICENTRE PROPENSITY SCORE MATCHED STUDY
THE OUTCOMES OF PATIENTS TREATED WITH 2ND AND 3RD LINE BIOLOGICAL IN PERIANAL CROHN’S DISEASE (PCD) – A MULTICENTRE PROPENSITY SCORE MATCHED STUDY

Stephane NANCEY  et al.

Item 1 - 20 / 20
1